Brii Biosciences Limited (Hong Kong Stock Exchange: 2137) has reported new Phase 2b data showing that 32.4% of participants in its ENRICH study maintained hepatitis B surface antigen loss 24 weeks after completing a sequential treatment regimen involving BRII-179, elebsiran and pegylated interferon alpha. Announced on 6 November 2026 for presentation at the American Association for the Study of Liver Diseases’ The Liver Meeting, the findings support further evaluation of immune priming as a strategy for achieving sustained responses in chronic hepatitis B.
In ENRICH, 62 of 148 participants achieved hepatitis B surface antigen loss at the end of treatment, representing 41.9%, while 48 maintained that outcome 24 weeks later. Separately, the ENHANCE study reported higher end-of-treatment surface antigen loss with concurrent triple therapy than with pegylated interferon alone, providing comparative evidence supporting the investigation of the combination.
The results advance Brii Bio’s attempt to develop treatment regimens that combine viral antigen suppression with immune-directed therapy. However, the reported outcomes remain Phase 2 findings, and surface antigen loss at a follow-up assessment should not automatically be equated with confirmed functional cure after withdrawal of all antiviral treatment.
The company’s clinical progress also faces a material development constraint. Brii Bio previously disclosed that an unresolved contractual dispute with Vir Biotechnology over elebsiran manufacturing technology transfer prevents it from committing to Phase 3 development of elebsiran-containing combinations until the relevant issues are satisfactorily resolved.
The combination of encouraging clinical findings and uncertainty over manufacturing access creates an unusually consequential decision point for the programme. The next stage will depend not only on the durability and safety of the treatment response but also on whether Brii Bio can establish a viable route to manufacturing and late-stage clinical development.
What do the Phase 2 ENRICH results reveal about BRII-179 immune priming in hepatitis B?
The ENRICH study was designed to investigate whether administering BRII-179 before antiviral and immune-modulating combination treatment could improve the likelihood of hepatitis B surface antigen loss. The approach builds on earlier findings from the ENSURE programme, particularly a cohort in which BRII-179 exposure appeared associated with improved responses.
In ENRICH, participants received BRII-179 as an immune-priming treatment at intervals of either two or three weeks over a 12-week period. This was followed by treatment involving elebsiran, an investigational small interfering RNA therapy, and pegylated interferon alpha.
Across the two BRII-179 dosing cohorts, 62 of 148 participants achieved hepatitis B surface antigen loss at the end of treatment. This corresponded to an overall response rate of 41.9%, based on the reported analysis population.
At 24 weeks after completing treatment, 48 of 148 participants maintained surface antigen loss, representing 32.4%. The follow-up finding is clinically relevant because it provides evidence of response persistence beyond the period of active combination treatment.
The difference between end-of-treatment and follow-up rates also demonstrates why durability must be evaluated independently. Some participants who achieve surface antigen loss during treatment may subsequently experience antigen reappearance, affecting the proportion with sustained response.
Brii Bio reported that the ENRICH findings were consistent with earlier observations from ENSURE Cohort 4. This provides support for the company’s hypothesis that immune priming before subsequent therapy may help improve response rates.
However, consistency across separate cohorts does not establish superiority over alternative treatment sequences. Patient selection, baseline antigen concentrations and other differences may influence the apparent performance of each regimen.
The company has not demonstrated through the November announcement that the ENRICH strategy produces higher functional cure rates than all available treatment alternatives. A confirmatory study with an appropriate comparator would be required to establish its relative clinical value.
Why does the 24-week post-treatment response matter more than the headline 41.9% rate?
Hepatitis B surface antigen loss is an important endpoint in the development of therapies intended to move beyond indefinite suppression of viral replication. Persistent surface antigen expression is one of the characteristic features of chronic hepatitis B infection, and its clearance may indicate a more favourable state of viral control.
However, surface antigen loss during treatment can be temporary. Viral antigen levels may increase again after therapy ends, meaning an apparently strong end-of-treatment result may not translate into a sustained response.
The ENRICH data provide information at both time points. The 41.9% end-of-treatment rate demonstrates the proportion achieving the specified antigen endpoint during the treatment programme, while the 32.4% rate at 24 weeks indicates how many maintained that outcome at the later assessment.
The absolute difference is 9.5 percentage points, corresponding to 14 fewer participants with maintained surface antigen loss than had achieved it at treatment completion. This calculation describes the reported endpoint counts and does not establish why individual participants lost or regained their responses.
The definition of functional cure also requires attention. It generally involves sustained hepatitis B surface antigen loss and appropriate viral suppression after the withdrawal of antiviral treatment. The ENRICH announcement specifies post-treatment HBsAg outcomes but does not provide every element necessary to establish that all qualifying participants remained off all hepatitis B medicines.
This distinction matters because participants receiving background nucleoside analogue treatment may maintain viral suppression even when an investigational regimen has ended. The conditions under which antiviral treatment is withdrawn influence how functional cure can be assessed.
Further follow-up will therefore be important to establish the stability of responses and determine whether participants can maintain viral control without conventional antiviral suppression.
The findings are encouraging within the context of investigational hepatitis B treatment, but their clinical significance will depend on the complete response definition, the status of background therapy and longer-term outcomes.
How did the ENHANCE triple combination compare with pegylated interferon alone?
The ENHANCE study examined whether combining BRII-179, elebsiran and pegylated interferon could improve hepatitis B surface antigen loss compared with established immune-modulating treatment alone.
In Part A1, participants received concurrent triple therapy or pegylated interferon monotherapy. The population consisted of adults with chronic hepatitis B whose viral replication was already suppressed.
At the end of treatment, 25 of 98 participants receiving triple therapy achieved surface antigen loss, representing 25.5%. In the pegylated interferon monotherapy group, five of 49 participants achieved the same endpoint, corresponding to 10.2%.
The absolute difference was approximately 15.3 percentage points. Brii Bio reported a p-value of 0.0301 for the end-of-treatment comparison, indicating statistical significance for that reported analysis.
At 24 weeks after treatment completion, surface antigen loss was maintained in 17 of 98 participants receiving triple therapy, or 17.3%, compared with three of 49 participants, or 6.1%, in the monotherapy group.
The follow-up difference was approximately 11.2 percentage points. However, the November announcement does not report a separate p-value establishing statistical significance for the 24-week comparison, so the numerical difference should not be described as independently confirmed statistical superiority at that time point.
The findings provide evidence that the investigational combination increased end-of-treatment surface antigen loss compared with pegylated interferon alone under the study conditions. They do not isolate the contribution of BRII-179 from that of elebsiran because the combination includes both investigational components.
This distinction will matter in future trial design. Determining which components are necessary to achieve a particular response could influence treatment complexity, tolerability, manufacturing requirements and cost.
Brii Bio previously reported in July that the ENHANCE end-of-treatment results had not shown improved surface antigen loss compared with selected historical ENSURE cohorts. That earlier observation does not contradict the current comparison against pegylated interferon monotherapy, because the comparisons involve different treatment groups and study contexts.
The newer follow-up results add information about durability, but the evidence does not establish that concurrent triple therapy is superior to the sequential ENRICH approach.
Can BRII-179-induced antibodies help identify patients most likely to benefit?
One of the more strategically important findings concerns antibodies directed against hepatitis B surface antigen. Brii Bio is investigating whether the immune responses generated following BRII-179 treatment can help identify participants more likely to achieve subsequent surface antigen loss.
BRII-179 is a recombinant protein-based immunotherapeutic candidate designed to express the Pre-S1, Pre-S2 and S hepatitis B surface antigens. Its purpose is to stimulate broader virus-specific immune responses as part of an investigational treatment strategy.
In ENHANCE Part A1, 49 of 98 participants receiving triple therapy achieved anti-HBs antibody concentrations of at least 10 IU/L at the end of treatment. Forty participants reached concentrations of at least 100 IU/L.
These represented 50.0% and 40.8% of the triple-therapy population, respectively. Brii Bio reported that antibody responses were more limited among participants receiving pegylated interferon alone.
The company also described exploratory findings suggesting an association between higher anti-HBs concentrations and the subsequent maintenance of surface antigen loss.
Such an association could become clinically useful if it helps identify patients likely to benefit from continued or intensified treatment. However, an exploratory correlation does not establish that anti-HBs concentration is a validated predictive biomarker.
The distinction between a treatment-induced immune response and a treatment-selection biomarker is important. A marker may correlate with eventual benefit because it reflects underlying biological responsiveness rather than because it independently predicts which patients would benefit from a particular regimen.
To support prospective treatment selection, the association would need to be reproduced in additional populations and evaluated using prespecified thresholds. Researchers would also need to demonstrate that acting on the marker improves outcomes compared with a strategy that does not use it.
For Brii Bio, a validated immune-response marker could eventually support more selective use of complex combination therapy. Such a strategy might help reduce unnecessary exposure among patients unlikely to respond, but those benefits remain hypothetical.
Does ENHANCE Part A2 support a shorter course of pegylated interferon?
ENHANCE Part A2 investigated a sequential treatment strategy intended to reduce the duration of pegylated interferon exposure. Participants received BRII-179 and elebsiran during an initial 24-week priming period, followed by elebsiran combined with pegylated interferon for another 24 weeks.
This reduced the planned pegylated interferon treatment duration from the 48 weeks used in the concurrent Part A1 regimen to 24 weeks.
At the end of treatment, 18 of 80 participants in Part A2 achieved hepatitis B surface antigen loss, representing 22.5%. At eight weeks after treatment completion, the proportion increased to 25.0%, corresponding to 20 of 80 participants.
The end-of-treatment response rate appeared numerically similar to the 25.5% reported in Part A1. However, the two regimens were evaluated under different treatment approaches, and the announcement does not establish formal noninferiority between them.
It would therefore be premature to conclude that halving the duration of pegylated interferon preserves equivalent clinical efficacy. A reliable equivalence or noninferiority conclusion requires an appropriately designed statistical comparison.
The potential practical value of a shorter pegylated interferon course is nevertheless substantial. Pegylated interferon treatment can be associated with systemic symptoms, laboratory abnormalities and other tolerability challenges that may complicate adherence.
Reducing exposure could potentially lower treatment burden if meaningful efficacy is maintained. However, the actual safety benefit would need to be demonstrated through comparative adverse event data rather than inferred from shorter dosing alone.
In Part A2, anti-HBs antibody responses also appeared relevant. At the end of the priming phase, 36 of 80 participants achieved anti-HBs concentrations of at least 10 IU/L, while 17 reached at least 100 IU/L.
Among those meeting the lower antibody threshold, 11 of 36 achieved surface antigen loss at treatment completion, representing 30.6%. Among participants who did not meet that threshold, seven of 44 achieved surface antigen loss, or 15.9%.
At eight weeks after treatment completion, 12 of the 36 antibody responders had achieved surface antigen loss, corresponding to 33.3%.
These findings support continued investigation of immune-response-guided treatment strategies. However, longer follow-up is required to determine whether the shorter regimen produces sufficiently durable outcomes.
Why are patients with higher baseline HBsAg levels important to Brii Bio’s development strategy?
Baseline hepatitis B surface antigen concentration is an important consideration in functional cure research because patients with higher antigen burdens can be more difficult to treat successfully.
In ENRICH, Brii Bio reported that 11 of 53 participants with baseline surface antigen concentrations above 1,000 IU/mL and up to 3,000 IU/mL maintained HBsAg loss at 24 weeks after treatment completion. This represented 20.8% of the specified subgroup.
In ENHANCE Part A1, six of 33 participants with baseline surface antigen levels above 1,000 IU/mL maintained HBsAg loss at the same follow-up point, representing 18.2%. None of the 18 participants in the corresponding pegylated interferon monotherapy subgroup achieved the endpoint.
Part A2 also generated responses among patients with higher baseline antigen levels. At treatment completion, seven of 48 participants with HBsAg above 1,000 IU/mL achieved surface antigen loss, representing 14.6%.
At eight weeks after treatment completion, eight of 48 participants in this subgroup had achieved surface antigen loss, corresponding to 16.7%.
These findings provide evidence of activity in a population where achieving surface antigen loss may be more challenging. However, subgroup sizes remain relatively small, and the different regimens and follow-up durations prevent reliable ranking of their relative performance.
The broader clinical question is whether immune priming can improve outcomes among patients who would otherwise have a low probability of functional cure.
If confirmed in larger studies, activity in higher-antigen populations could strengthen the commercial relevance of the programme. However, the current findings do not establish an approved indication or a validated patient-selection strategy.
What safety findings emerged across the ENRICH and ENHANCE studies?
Brii Bio characterised the ENRICH and ENHANCE treatment regimens as generally tolerable during the reported study periods. The company stated that most commonly reported adverse events were consistent with the known adverse effect profile of pegylated interferon alpha.
In ENHANCE Part A1, no new or unexpected safety signals were identified in the disclosed analysis. The company did not provide a comprehensive numerical breakdown of serious adverse events, Grade 3 or higher events or treatment discontinuations in the November announcement.
In Part A2, Grade 3 or higher adverse events were described as rare during the initial BRII-179 and elebsiran priming phase. Following the addition of pegylated interferon, the safety findings were generally consistent with its known profile.
Brii Bio also reported that certain adverse events occurred less frequently in Part A2 than in Part A1, alongside the shorter pegylated interferon treatment duration. However, the available disclosure does not provide sufficient comparative detail to establish that one regimen is statistically safer than the other.
Longer-term safety will remain an important consideration for hepatitis B functional cure strategies. These treatments may involve immune stimulation and substantial changes in viral antigen expression, making liver enzyme monitoring and assessment of hepatic complications important.
A successful future regimen will need to demonstrate an acceptable balance between the probability of sustained response and the adverse effects associated with treatment.
Reducing the duration of an established therapy could be advantageous, but only if efficacy remains sufficiently durable and the safety benefits are clinically meaningful.
How could the dispute with Vir Biotechnology affect Brii Bio’s Phase 3 ambitions?
The most significant commercial constraint on Brii Bio’s hepatitis B programme concerns access to elebsiran manufacturing technology. Elebsiran is an investigational small interfering RNA therapy designed to degrade hepatitis B viral RNA and reduce surface antigen production.
Brii Bio obtained an exclusive licence from Vir Biotechnology in 2020 covering elebsiran development and commercialisation in Greater China. The molecule is a central component of the combination regimens evaluated in ENRICH and ENHANCE.
In April 2026, Brii Bio initiated arbitration proceedings against Vir Biotechnology concerning a contractual dispute involving manufacturing technology transfer obligations. Brii Bio alleged that Vir had breached provisions of their agreements and sought contractual performance and financial relief.
Those allegations remain disputed contractual claims rather than established findings of wrongdoing. The available public disclosures do not establish a final arbitration decision or resolution of the parties’ differences.
In its August 2026 interim results, Brii Bio stated that the arbitration remained unresolved as of its last reported status. The company also indicated that it could not commit to or invest in Phase 3 development of elebsiran-containing combinations until the claims were satisfactorily resolved.
The November clinical announcement does not disclose a resolution that changes that development position.
The operational significance is considerable because positive clinical data cannot independently guarantee access to the manufacturing processes required for late-stage trials and commercial supply. A developer must be able to produce investigational material consistently and under applicable pharmaceutical quality requirements.
Technology transfer can involve manufacturing know-how, analytical methods, process validation and access to specialised production capabilities. Difficulties securing those elements may delay trials even when the supporting clinical evidence is strong.
For Brii Bio, the dispute therefore represents a development dependency rather than a peripheral legal matter. Its ability to convert the ENRICH and ENHANCE findings into a registrational programme may depend on securing an acceptable manufacturing and contractual pathway.
What do Brii Biosciences’ financial results reveal about its ability to fund future development?
Brii Bio’s interim financial results provide context for the company’s ability to continue research while managing uncertainty around elebsiran.
At 30 June 2026, the company reported bank deposits and cash and cash equivalents of RMB1.77 billion, compared with RMB1.94 billion at the end of 2025. It stated that the available financial resources were expected to support operations through 2029.
Research and development expenditure for the first half of 2026 was RMB98.3 million, compared with RMB117.0 million in the corresponding period of 2025. The decline reflected measures including organisational optimisation, lower external contracting costs and the winding down of certain Phase 2 activities.
The company reported a net loss of approximately RMB101.0 million for the six-month period, compared with RMB148.8 million a year earlier.
These figures indicate that Brii Bio retains meaningful financial resources, but the existence of cash does not eliminate contractual or manufacturing constraints. The company has explicitly linked its ability to advance elebsiran-containing combinations into Phase 3 to the satisfactory resolution of the underlying dispute.
The distinction is important for investors because clinical progress and development readiness are separate considerations. A programme can produce encouraging trial results while remaining unable to progress because of supply, licensing or operational restrictions.
Brii Bio has also been developing internal RNA technology capabilities, including its BRiSC dual-targeting small interfering RNA discovery platform announced in October 2026. This provides a broader research direction, but the newer platform does not automatically replace elebsiran within the established ENRICH and ENHANCE clinical regimens.
The company will therefore need to determine how it allocates resources between existing hepatitis B programmes and emerging research opportunities.
How should investors interpret Brii Bio’s clinical progress and stock performance?
Brii Biosciences shares were quoted at HK$1.025 on 5 November 2026, unchanged from the preceding session and approximately 5.7% higher over the previous five trading sessions.
The stock’s 52-week range extended from approximately HK$0.815 to HK$1.90, illustrating substantial valuation volatility. The company remained a clinical-stage development business whose investment outlook depends heavily on the probability and timing of pipeline progression.
The latest Phase 2 findings support the biological and clinical rationale for BRII-179-based treatment strategies. However, they do not remove the uncertainty surrounding elebsiran or establish when a Phase 3 programme could begin.
From an investor perspective, the most consequential issue is whether Brii Bio can translate its clinical evidence into an executable late-stage development plan.
The company’s cash position provides financial flexibility, but the value of that flexibility depends on access to the necessary therapeutic components and manufacturing capabilities.
The November announcement should therefore be viewed as an encouraging clinical evidence update rather than a completed regulatory de-risking event. The programme remains investigational and has not secured marketing authorisation for chronic hepatitis B.
Can BRII-179 immune priming become a practical strategy for hepatitis B functional cure?
Brii Bio’s emerging strategy combines several different therapeutic objectives. BRII-179 is intended to stimulate virus-specific immune responses, elebsiran reduces hepatitis B viral RNA, and pegylated interferon provides additional antiviral and immune-modulating activity.
The sequencing of these components may influence both response and tolerability. ENRICH investigates priming before subsequent combination treatment, while ENHANCE evaluates concurrent therapy and a shorter sequential regimen.
The clinical evidence suggests that BRII-179-associated immune responses may help identify patients more likely to achieve surface antigen loss. However, the programme has not yet demonstrated that using antibody responses to guide treatment decisions produces superior clinical outcomes.
The next scientific priorities include longer follow-up, clearer characterisation of sustained responses and confirmation of the relationship between immune markers and treatment benefit. Future studies will also need to determine whether a shorter pegylated interferon regimen can maintain sufficiently durable efficacy with a more favourable treatment burden.
Regulatory development remains dependent on an appropriately designed confirmatory programme. Such a trial would need to establish the relevant efficacy endpoint, adequately characterise safety and support an acceptable manufacturing and quality package.
The long-term commercial opportunity is substantial because current hepatitis B therapies generally suppress viral replication rather than consistently producing functional cure. However, the size of the global patient population cannot be translated directly into obtainable revenue for an investigational combination.
A practical regimen must demonstrate acceptable efficacy across defined patient populations, manageable toxicity, feasible administration and sustained treatment-free outcomes. It must also be supported by a reliable manufacturing supply chain and an economically viable commercial model.
Brii Bio’s November 2026 findings provide further evidence that immune priming and antiviral combination therapy can produce sustained hepatitis B surface antigen loss in a meaningful proportion of treated participants. The 32.4% ENRICH follow-up rate and the comparative ENHANCE results strengthen the scientific rationale for continued research, while the shorter Part A2 regimen offers a potentially useful direction for reducing treatment burden. The decisive next step is translating those findings into an executable late-stage development programme, a process that will depend as much on resolving the elebsiran manufacturing constraint as on establishing durable clinical benefit.
